Midday trading saw sharp moves across technology, biotech, retail and financials as investors digested deal news, clinical trial updates, analyst rating changes and political developments abroad. Shares of SpaceX-affiliated entities jumped alongside optimism around Taiwan Semiconductor Manufacturing’s role in Elon Musk’s Terafab plan, while Sphere Entertainment sank after a downgrade citing a faster-than-expected weakening in demand for “The Wizard of Oz.”
Key takeaways
- SpaceX rose about 6% and TSMC gained around 2% after Elon Musk confirmed discussions with Taiwan Semiconductor Manufacturing regarding support for Terafab’s Texas operations.
- Sphere Entertainment fell roughly 12% following a Craig-Hallum downgrade to hold, with concerns that “Wizard of Oz” demand is softening faster than anticipated.
- Vaxcyte surged about 30% after reporting positive Phase 3 topline results for its pneumococcal conjugate vaccine in adults aged 50 and over.
- Brazil-focused stocks rallied after an election result in which right-wing candidate Flavio Bolsonaro edged incumbent Luiz Inacio Lula Da Silva by about 2 percentage points, lifting sentiment toward the market.
- PTC jumped about 33% on the announcement that Schneider Electric will acquire the software company for $205 per share.
What drove the biggest equity moves
Terafab talks lift semiconductor-linked optimism
Shares tied to the Terafab chip venture moved on fresh confirmation from Elon Musk that he has discussed having Taiwan Semiconductor Manufacturing help operate Terafab’s Texas factories. Intel, which is also involved in Terafab, slid about 2% in the same window. TSMC climbed roughly 2%, while SpaceX shares rose about 6%, reflecting investors’ focus on execution and supply-chain support for the U.S. chip push.
Entertainment demand concerns weighed on Sphere Entertainment
Sphere Entertainment shares dropped about 12% after Craig-Hallum Capital downgraded the stock to hold from buy, according to StreetAccount. The downgrade centered on management commentary that demand for “The Wizard of Oz” is softening faster than anticipated, raising risk to second-half 2026 and first-half 2027 estimates.
Vaccine trial results sparked a sharp biotech rally
Vaxcyte shares jumped about 30% after the company reported positive topline results from a Phase 3 trial of its pneumococcal conjugate vaccine in adults aged 50 and over. The immune responses were described as comparable to Pfizer’s Prevnar 20 and Merck’s Capvaxive, giving investors confidence that the program could support commercial and regulatory expectations.
Short-seller scrutiny pressured Millrose and Lennar
Millrose Properties and Lennar each fell roughly 6% after a short report by Hunterbrook Media called into question the economics of Millrose’s single-family rental investments and Lennar’s potential influence over the strategy.
Deal news propelled PTC higher
PTC shares surged about 33% after the company agreed to be acquired by Schneider Electric for $205 per share, valuing PTC’s equity at more than $22 billion. The companies said the transaction is expected to close by the third quarter of 2027, putting the stock’s move squarely in “takeover arbitrage” territory for investors tracking deal certainty and timing.
Analyst upgrades and rating changes in the spotlight
Microsoft climbed after an AI-and-security upgrade
Microsoft rose more than 1% following an upgrade to buy from Melius Research. Analyst Ben Reitzes argued that Microsoft has an edge in artificial intelligence as security becomes a central priority, framing the company’s leadership in security, governance and what he described as an “AI CYA” strategy.
DraftKings popped on a Bank of America note
DraftKings shares advanced more than 7% after Bank of America upgraded the stock to buy from neutral. Julie Hoover said prediction markets could be a “win-win,” pointing to expectations for $400 million in fees in 2027 and $200 million to $400 million for market making.
Wells Fargo gained on expectations for steadier funding
Wells Fargo rose around 1% after Morgan Stanley upgraded the stock to overweight from equal weight. In a note, analyst Manan Gosalia said normalizing balance sheet growth could ease funding pressure, stabilize net interest margin, and increase conviction in a path toward higher returns.
Estee Lauder and Harley-Davidson benefited from new bullish stances
Estee Lauder gained about 2% after Barclays upgraded it to overweight from equal weight, citing a constructive view on growth and earnings over the next several years. Harley-Davidson rose roughly 10% after a Citi upgrade to buy from neutral, with Citi attributing potential upside to a major product introduction, cost savings and possible earnings tailwinds from LiveWire.
Brazil rally tied to election outcome
Brazil-focused equities surged after results from Sunday’s presidential election showed right-wing candidate Flavio Bolsonaro edging incumbent Luiz Inacio Lula Da Silva by around 2 percentage points. The iShares MSCI Brazil ETF (EWZ) jumped 13%, while U.S.-listed shares of Itau Unibanco and Banco Bradesco surged 16% and 19%, respectively. Mercado Libre, a company that lists Brazil as a major market, advanced about 8%.
The reaction underscored how quickly global investors can reprice regional risk and policy expectations following election outcomes—particularly for markets where fiscal and regulatory direction are key inputs into equity valuation and capital flows.
What to watch next
Investors will likely watch for follow-through in the companies moving on deal and trial catalysts, especially developments that clarify timelines and execution risks. In the near term, attention is also expected to return to broader earnings guidance and macro signals that influence discount rates—particularly as markets continue to price outcomes tied to interest rates, inflation and policy direction.
